Stereotaxis (STXS) Research & Development (2010 - 2026)
Stereotaxis (STXS) posted quarterly Research & Development of $2.6 million for Q1 2026, down 16.87% year-over-year from $3.1 million in Q1 2025, and down 54.64% quarter-over-quarter from $5.8 million in Q4 2025.
Stereotaxis (STXS) Research & Development (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Research & Development for 17 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 16.87% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $14.2 million (down 5.34% YoY), while the FY2025 annual figure was $12.4 million, up 0.57% from the prior year.
- Research & Development eased to $2.6 million in Q1 2026 per STXS's latest filing, from $5.8 million in the prior quarter.
- Across five years, Research & Development topped out at $5.8 million in Q4 2025 and bottomed at $688000.0 in Q4 2023.
- Historically, Research & Development has averaged $3.1 million across 5 years, with a median of $3.1 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development sank 71.33% — and 2024, when it soared 685.17%.
- Stereotaxis' Research & Development stood at $2.4 million in 2022, then tumbled by 71.33% to $688000.0 in 2023, then jumped by 685.17% to $5.4 million in 2024, then rose by 6.81% to $5.8 million in 2025, then slumped by 54.64% to $2.6 million in 2026.
- Business Quant data shows STXS's Research & Development at $2.6 million in Q1 2026, $5.8 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 688,000.00 |
| Sep 30, 2023 | 3.10 Mn |
| Jun 30, 2023 | 3.34 Mn |
| Mar 31, 2023 | 3.15 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 3.11 Mn |
| Jun 30, 2022 | 2.89 Mn |
| Mar 31, 2022 | 2.45 Mn |
| Dec 31, 2021 | 4.36 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 3.05 Mn |